What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025Blood

Reassessing voxelotor safety and efficacy: Real-world outcomes from the ASH research collaborative data hub

View Full Paper

Ask AI

Bookmark

Authors

CQCharles T. QuinnCincinnati Children's Hospital Medical Center AKAbdullah KutlarAugusta University

Discussion

Member takes

Implication

Observational analysis shows limited benefit of voxelotor on Hb and reticulocyte counts in sickle cell disease, indicating concerns over safety and efficacy.

Key Points

Real-world analysis indicates voxelotor led to a small increase in Hb levels.
Patients on voxelotor experienced no increase in crucial clinical events during treatment.
Longitudinal analysis suggests a decrease in reticulocyte counts observed among patients.
Despite higher risks of severe SCD in the voxelotor cohort, no evident increase in hospitalization rates was noted.

Cite This Study

Quinn et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d539 https://doi.org/10.1182/blood-2025-6226

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows limited benefit of voxelotor on Hb and reticulocyte counts in sickle cell disease, indicating concerns over safety and efficacy.

Reassessing voxelotor safety and efficacy: Real-world outcomes from the ASH research collaborative data hub

Discussion

Member takes

Implication

Key Points

Cite This Study

Reassessing voxelotor safety and efficacy: Real-world outcomes from the ASH research collaborative data hub

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider